Susunod

Auto-play

Biomarker directed therapies in biliary tract cancers

1 Mga view • 07/01/23
Ibahagi
I-embed
administrator
administrator
Mga subscriber
0

Approximately 40% of biliary tract cancer harbor gene alterations that can be targeted with precision-based medicines. James J. Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the targetable mutations in biliary tract cancer and the future of the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Magpakita ng higit pa
0 Mga komento sort Pagbukud-bukurin Ayon
Mga Komento sa Facebook

Susunod

Auto-play